Trial Profile
Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AVIRIX
- 17 Jul 2012 New trial record